Anticardiolipin antibodies in patients with rheumatic diseases

Fort, John G.; Cowchock, F. Susan; Abruzzo, John L.; Smith, J. Bruce

doi:10.1002/art.1780300705

Cited by 122 publications

(37 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients with high titers of aPL are prone to a variety of thrombotic episodes and to fetal loss (4)(5)(6)(7)(8)(9)(10)(11)(12)(13)(14)(15)(16). Antiphospholipid antibodies can be detected by lupus anticoagulant (LAC) assay or by enzyme immunoassays (EIA) against phospholipids.…”

mentioning

confidence: 99%

Antibodies to β₂‐glycoprotein I and clinical manifestations in patients with systemic lupus erythematosus

Tsutsumi

Matsuura

Ichikawa

et al. 1996

Arthritis & Rheumatism

211

109

View full text Add to dashboard Cite

Objective. To investigate whether anticardiolipin antibodies (aCL) in patients with systemic lupus erythematosus (SLE) bind to β2‐glycoprotein I (β2GPI), and to search for a relationship between the presence of IgG and/or IgM anti‐β2GPI antibody and clinical manifestations in SLE patients. Methods. IgG and IgM anti‐β2GPI in 308 Japanese SLE patients were measured using phospholipid‐independent enzyme immunoassays. Relationships to clinical histories and to various laboratory data were examined. Results. The values of anti‐β2GPI and aCL, as measured by conventional enzyme immunoassay, showed a strong correlation, but the anti‐β2GPI assay was more useful in distinguishing β2GPI‐dependent aCL from β2GPI‐independent aCL. The presence of IgG anti‐β2GPI was associated with an increased frequency of a history of thrombosis. Comparisons of various laboratory data suggested that the titer of anti‐β2GPI may fluctuate with disease activity. Conclusion. The results suggest that pathogenic aCL is directed against structurally altered β2GPI and that enzyme immunoassay for anti‐β2GPI may prove useful in evaluating the risk of thrombosis and monitoring the clinical course in patients with SLE.

show abstract

mentioning

confidence: 99%

Antibodies to β₂‐glycoprotein I and clinical manifestations in patients with systemic lupus erythematosus

Tsutsumi

Matsuura

Ichikawa

et al. 1996

Arthritis & Rheumatism

211

109

View full text Add to dashboard Cite

show abstract

“…Among the more common disease conditions are the primary antiphospholipid syndrome (41), SLE (42), and other less common conditions such as Sjogren's syndrome, rheumatoid arthritis, and scleroderma (43). There is also evidence that these antibodies can arise in many unrelated conditions, such as human immunodeficiency virus infection (44) or endometriosis (25), and in patients with hematologic malignancies.…”

Section: Use Of Corticosteroids To Manage Disease In Women With Aplmentioning

confidence: 99%

Clinical rheumatologic applications of reproductive immunology. Facts, fiction, and fancy

Wallace

Druzin

Lahita

1997

Arthritis & Rheumatism

View full text Add to dashboard Cite

“…In the present study, the frequencies of LAC-and ACL-positive patients were 27.2% and 34.7% , respect ively. Reports of the prevalence of LAC in SLE patients vary from 5 to 73% (10,13,14), and that ofACL from 21 to 63% (10,14,15). According to a previous report (13), the average prevalence of LAC is 28% and that of ACL is 42%.…”

Section: Patientsmentioning

confidence: 99%

Distribution and Clinical Significance of Lupus Anticoagulant and Anticardiolipin Antibody in 349 Patients with Systemic Lupus Erythematosus.

et al. 1992

View full text Add to dashboard Cite

Samples from 349 patients with systemic lupus erythematosus (SLE) were tested simul taneously for lupus anticoagulant (LAC) and anticardiolipin antibodies (ACL). LAC was detected in 27.2% of 349 SLE patients by a modified mixing kaolin clotting time. ACL was detected in 34.7% by enzyme-linked immunosorbent assay. Only half of the patients who had LAC or ACL were positive for both of them. In addition, isotypes of ACL in these patients were studied. The IgG isotype was detected in 81.8% of 121 patients, and more than half had only the IgG isotype. When clinical features of patients with LAC or ACL were studied, the incidence of thrombosis, fetal loss, and thrombocytopenia were significantly higher in both groups compared with patients without LAC or ACL. In particular, the patients with both LAC and ACL showed the highest risk of fetal loss (89%) during pregnancy. These results indicate that LAC and ACL are detected in partly different groups of SLE patients, but both of these groups are clinically similar.

show abstract

Anticardiolipin antibodies in patients with rheumatic diseases

Abstract: Systemic lupus erythematosus (SLE) and other connective tissue diseases (CTD) are characterized by a diverse antibody production which is generally not organ-or receptor-specific. Among these autoantibod--~

Cited by 122 publications

References 19 publications

Antibodies to β₂‐glycoprotein I and clinical manifestations in patients with systemic lupus erythematosus

Antibodies to β₂‐glycoprotein I and clinical manifestations in patients with systemic lupus erythematosus

Clinical rheumatologic applications of reproductive immunology. Facts, fiction, and fancy

Distribution and Clinical Significance of Lupus Anticoagulant and Anticardiolipin Antibody in 349 Patients with Systemic Lupus Erythematosus.

Contact Info

Product

Resources

About

Anticardiolipin antibodies in patients with rheumatic diseases

Abstract: Systemic lupus erythematosus (SLE) and other connective tissue diseases (CTD) are characterized by a diverse antibody production which is generally not organ-or receptor-specific. Among these autoantibod--~

Cited by 122 publications

References 19 publications

Antibodies to β2‐glycoprotein I and clinical manifestations in patients with systemic lupus erythematosus

Antibodies to β2‐glycoprotein I and clinical manifestations in patients with systemic lupus erythematosus

Clinical rheumatologic applications of reproductive immunology. Facts, fiction, and fancy

Distribution and Clinical Significance of Lupus Anticoagulant and Anticardiolipin Antibody in 349 Patients with Systemic Lupus Erythematosus.

Contact Info

Product

Resources

About

Antibodies to β₂‐glycoprotein I and clinical manifestations in patients with systemic lupus erythematosus

Antibodies to β₂‐glycoprotein I and clinical manifestations in patients with systemic lupus erythematosus